7164-80-9

Basic information

• Product Name: Benzamide, 2-hydroxy-N-(4-methylphenyl)-
• CAS NO: 7164-80-9
• Molecular Formula: C14H13NO2
• Molecular Weight: 227.263
• Mol File: 7164-80-9.mol
• Article Data: 15

Chemical Properties

• CAS DataBase Reference: Benzamide, 2-hydroxy-N-(4-methylphenyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzamide, 2-hydroxy-N-(4-methylphenyl)-(7164-80-9)
• EPA Substance Registry System: Benzamide, 2-hydroxy-N-(4-methylphenyl)-(7164-80-9)

Safety Data

• Hazardous Substances Data: 7164-80-9(Hazardous Substances Data)

Upstream product

• 118-55-8 phenyl Salicylate 
• 106-49-0 p-toluidine 
• 69-72-7 salicylic acid 
• 1441-87-8 salicyloyl chloride 
• 90-02-8 salicylaldehyde 
• 936-02-7 2-Hydroxybenzoylhydrazine 
• 341509-79-3 4-salicyloylhydrazinomethylene-2-phenyloxazol-5(4H)-one 
• 118-61-6 2-hydroxy-benzoic acid ethyl ester 
• 119-36-8 methyl salicylate 

Downstream Products

• 81500-04-1 2-oxiranylmethoxy-N-p-tolyl-benzamide 
• 1411685-41-0 C₂₀H₂₇NOSSi 
• 88016-71-1 2-(2'-Hydroxyphenyl)-6-methyl-benzthiazol 
• 1369423-66-4 3-(tetrahydro-2H-pyran-2-yl)-11-(p-tolyl)benzo[f]pyridazino[4,5-b][1,4]oxazepine-4,10(3H,11H)-dione 
• 1321192-21-5 7-nitro-10-(p-tolyl)dibenzo[b,f][1,4]oxazepin-11(10H)-one 
• 1206874-31-8 benzyl (S)-1-((2-(p-tolylcarbamoyl)phenoxy)carbonyl)-2-methylpropylcarbamate 
• 1161410-04-3 C₂₁H₁₄N₂O₂ 
• 1161410-13-4 C₁₉H₁₄N₂O₂ 
• 7133-79-1 3-(4-methylphenyl)-2H-1,3-benzoxazine-2,4(3H)-dione 
• 4638-50-0 5-chloro-4'-methylsalicylanilide 

Relevant articles and documents

Synthesis and biological evaluation of JL-A7 derivatives as potent ABCB1 inhibitors

Cancer chemotherapy failure is often due to the overexpression of ATP-binding cassette (ABC) transporters (particularly ABCB1), resulting in a variety of structurally and pharmacologically unrelated drugs efflux. The multidrug resistance (MDR) phenomenon could be reversed by ABCB1 inhibitors. Now, JL-A7 as the lead compound based on a triazol-N-ethyl-tetrahydroisoquinoline scaffold, 18 compounds were designed and synthesized. Substitution in para positions yielded high activities toward ABCB1. Moreover, compound 5 could effectively block the drug efflux function of ABCB1 and increase the accumulation of anti-cancer drugs to achieve effective treatment concentration in MDR cells.

AMIDOPHENOXYPROPANOLAMINES

The use of compounds of formula wherein R2, R3, R4, R5, R6 and R7 have several meanings, for the treatment of disorders mediated by protozoan organisms, novel compounds of the above formula

Synthesis and antiproliferative activities against Hep-G2 of salicylanide derivatives: Potent inhibitors of the epidermal growth factor receptor (EGFR) tyrosine kinase

A series of salicylanilide derivatives (compounds 1-32) were synthesised by reacting substituted salicylic acids and anilines. The chemical structures of these compounds were determined by 1H-NMR, electrospray ionisation mass spectrometry (ESI-MS) and elemental analysis. The compounds were assayed for their antiproliferative activities against the Hep-G2 cell line by the 3-(4,5-dimethylthylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) method. Among the compounds tested, 22 and 28 showed the most favouable antiproliferative activities with 50% inhibitory concentration (IC50) values of 1.7 and 1.3 μM, respectively, which were comparable to the positive control of 5-fluorouracil (IC50 = 1.8 μM). A solid-phase ELISA assay was also performed to evaluate the ability of compounds 1-32 to inhibit the autophosphorylation of the epidermal growth factor receptor tyrosine kinase (EGFR TK). Docking simulations of 22 and 28 were carried out to illustrate the binding mode of the molecule into the EGFR active site, and the result suggested that both compounds 22 and 28 could bind the EGFR kinase well.